Macrophage Inhibitory Cytokine-1 (MIC-1) as A Biomarker for Diagnosis and Prognosis of Stage I-II Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2016.04.05
- VernacularTitle:巨噬细胞抑制因子-1与早期非小细胞肺癌诊断及预后相关性
- Author:
LIU YUNING
1
;
WANG XIAOBING
;
WANG TENG
;
ZHANG CHAO
;
ZHANG KUNPENG
;
ZANG RUOCHUAN
;
ZHI XIUYI
;
ZHANG WEI
;
SUN KELIN
Author Information
1. 北京协和医学院中国医学科学院肿瘤医院胸外科
- Keywords:
Lung neoplasms;
Macrophage inhibitory cytokine-1;
Tumor biomarker;
Prognosis
- From:
Chinese Journal of Lung Cancer
2016;19(4):207-215
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Increased macrophage inhibitory cytokine-1 (MIC-1), member of trans-forming growth factor-β(TGF-β) superfamily, was found in patients serum with epithelial tumors. hTerefore, our aim was to delineate the diagnostic and prognostic value of serum MIC-1 in patients with stage I-II non-small cell lung cancer (NSCLC). Methods A total of 152 consecutive patients with stage I–II NSCLC were prospectively enrolled and underwent follow up atfer total resection of tumor. Serum MIC-1 level was detected in lung cancer patients by ELISA, 48 benign pulmonary disease patients and 105 healthy controls, and was correlated with clinical features and prognosis of patients. Results hTe level of MIC-1 of NSCLC patients was signiifcantly higher than that of controls (P<0.001) and benign pulmonary disease patients (P<0.001). A threshold of 1,000 pg/mL could be used to diagnose early-stage NSCLC with 70.4%sensitivity and 99.0%speci-ifcity. hTe level of MIC-1 was associated with elder age (P=0.001), female (P=0.03) and T2 (P=0.022). A threshold of 1,465 pg/mL could identify patients with early poor outcome with 72.2%sensitivity and 66.1%speciifcity. hTe overall 3-year survival rate in patients with high level of MIC-1 (≥1,465 pg/mL) was signiifcantly lower than that of patients with low MIC-1 level (77.6%vs 94.8%). Multivariable Cox regression revealed that a high level of MIC-1 was an independent risk factor for compro-mised overall survival (HR=3.37, 95%CI:1.09-10.42, P=0.035). Conclusion High level of serum MIC-1 could be served as a potential biomarker for diagnosis and poorer outcome in patients with early-stage NSCLC.
